Average Co-Inventor Count = 4.22
ph-index = 19
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Dana-farber-cancer Institute Inc. (139 from 1,192 patents)
2. Irm LLC (26 from 151 patents)
3. The Scripps Research Institute (10 from 1,184 patents)
4. The General Hospital Corporation (8 from 2,857 patents)
5. The Broad Institute, Inc. (6 from 427 patents)
6. Novartis Ag (4 from 3,915 patents)
7. Harvard College (4 from 2,944 patents)
8. Cornell University (3 from 1,350 patents)
9. Whitehead Institute for Biomedical Research (3 from 302 patents)
10. Yale University (2 from 1,317 patents)
11. University Court of the University of Dundee (2 from 35 patents)
12. Other (1 from 832,347 patents)
13. Children's Medical Center Corporation (1 from 1,030 patents)
14. Beth Israel Deaconess Medical Center, Inc. (1 from 511 patents)
15. University of Miami (1 from 373 patents)
172 patents:
1. 12329821 - Degradation of bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use
2. 12331037 - Pyrimidines as EGFR-inhibitors and methods of treating disorders
3. 12325725 - Cyclin-dependent kinase degraders and methods of use
4. 12318452 - Degraders of WEE1 kinase
5. 12281126 - Inhibitors of cyclin-dependent kinase 7 and uses thereof
6. 12275731 - Azaindole inhibitors of wild-type and mutant forms of LRRK2
7. 12233128 - Degraders that target ALK and therapeutic uses thereof
8. 12234220 - Immunomodulatory compounds
9. 12227488 - Small molecule degraders of Helios and methods of use
10. 12209076 - Imidazolyl kinase inhibitors and uses thereof
11. 12187701 - Taire family kinase inhibitors and uses thereof
12. 12168663 - Inhibitors of cyclin-dependent kinase 7 (CDK7)
13. 12161649 - Inhibitors of EGFR and methods of use thereof
14. 12157738 - Macrocyclic inhibitors of ALK, TRKA, TRKB, and ROS1
15. 12157741 - Macrocyclic inhibitors of DYRK1A